PDL BioPharma Earnings: Here’s Why Investors are Buying Shares Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

PDL BioPharma, Inc. (NASDAQ:PDLI) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 1.48%.

PDL BioPharma, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased 19.23% to $0.62 in the quarter versus EPS of $0.52 in the year-earlier quarter.

Revenue: Rose 14.06% to $143.6 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: PDL BioPharma, Inc. reported adjusted EPS income of $0.62 per share. By that measure, the company beat the mean analyst estimate of $0.54. It beat the average revenue estimate of $138.2 million.

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business